Navigation Links
Monoclonal Antibodies Market in Rheumatoid Arthritis to 2018 - Market Characterized by Large and Diversified Pipeline and Low Threat of Biosimilar Sales Erosion
Date:6/6/2013

DUBLIN, June 6, 2013 /PRNewswire/ --

Research and Markets (http://www.researchandmarkets.com/research/272vtc/monoclonal) has announced the addition of the "Monoclonal Antibodies Market in Rheumatoid Arthritis to 2018 - Market Characterized by Large and Diversified Pipeline and Low Threat of Biosimilar Sales Erosion" report to their offering.

     (Logo: http://photos.prnewswire.com/prnh/20130307/600769)

The currently marketed monoclonal antibodies are clinically and commercially highly successful products in the rheumatoid arthritis market, constituting four of the global top 20 best-selling drugs. The unique density of monoclonal antibodies that are approved for this indication, significant market exclusivity expiries in the forecast period and yet more monoclonal antibodies in development will change the dynamics in and this highly lucrative market in the forecast period until 2018.

Scope of this research

- The current therapeutic environment in the treatment of RA across the top seven developed markets, including the US, Germany, France, the UK, Italy, Spain and Japan.

- Analysis of the competitive environment for monoclonal antibodies with strong data and evidence-based profiling of marketed products, including comparative benchmarking and assessment of efficacy and safety profiles as well as differentiating product features.

- A detailed pipeline analysis for monoclonal antibodies in rheumatoid arthritis including individual product profiles, a comparative efficacy and safety profile heat map analysis of the most promising pipeline products as well as analyses on the distribution of molecule types across the RA developmental pipeline, the molecular targets of pipeline mAbs and the developmental program types. In addition, detailed analyses of the clinical trial failure rates, the clinical trial durations by phase and clinical trial sizes by participant numbers are provided.

- Market data on the geographical landscape and therapeutic landscape, including market size, annual cost of therapy, treatment usage patterns such as disease population and prescription populations.

- Market forecasts across the US, the top five countries in Europe (EU5) - Germany, France, the UK, Italy, and Spain- as well as Japan. The multiple scenario forecasts take a range of factors that are likely to vary into account and provide a clear perspective on the level of the potential degree of variance in the market sizes.

- Key market drivers and barriers

- the major deals that have taken place in the monoclonal antibodies market in rheumatoid arthritis in recent years. Coverage includes Mergers and Acquisitions (M&As) as well as co-development and licensing agreements, which are segmented on the basis of geography and total value. A concomitant analysis of the licensing deal values for products by molecule types and molecular targets is also provided.

Reasons to buy

- Understand the competitive environment for monoclonal antibodies

- Develop key strategic repositioning initiatives by studying the repositioning trends and strategies of current competitors

- Understand the clinical and commercial impact of the growing diversification of the molecular targets of monoclonal antibodies in the pipeline and identify potential first-in-class products

- Assess the potential clinical and commercial impact of current late-stage pipeline molecules on the RA market in the forecast period

- Use the clinical trial failure rate analysis to assess the risk profiles of current and/or future developmental programs for monoclonal antibodies in RA

- Use key benchmark data to forecast costs of developmental programs for monoclonal antibodies in RA by using proprietary clinical trial size and duration analyses

- Exploit in-licensing and out-licensing opportunities by identifying products that might fill their portfolio gaps

- Use proprietary data analyses to assess the market value of pipeline molecules for in-licensing and out-licensing opportunities

For more information visit http://www.researchandmarkets.com/research/272vtc/monoclonal

 

Research and Markets
Laura Wood , Senior Manager.
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716



'/>"/>
SOURCE Research and Markets
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Aridis Pharmaceuticals Announces Acquisition of Monoclonal Antibody Products and Technologies From Kenta Biotech
2. GeneTex Introduces New Mouse Monoclonal Antibody Against the Ten-Eleven Translocation 1 (TET1) Protein for DNA Methylation/Epigenetics Research
3. Diversified Pipeline and Low Threat of Biosimilar Sales Erosion To Drive Growth Of Monoclonal Antibodies Market
4. Glenmark Announces a New Discovery and the Initiation of IND Enabling Studies of a Novel Monoclonal Antibody Targeting OX40
5. Monoclonal Antibody Partnering Terms & Agreements Discussed in New Report Now Available at MarketPublishers.com
6. Acute Lymphocytic Leukemia: Impressive Results With the Monoclonal Antibody Blinatumomab in Patients With Refractory Disease
7. LifeSpan Adds 1,200+ New Antibodies To Its Proprietary IHC-plus(TM) Product Line
8. Cancer Antibodies: Drug Target Atlas and Competitive Outlook
9. X-BODY BioSciences to Present Novel Methods of Selecting for Antibodies Against Targets on Live Cells at CHIs Protein Engineering Summit
10. Avaxia Biologics, Inc. Closes $4.1 Million Series A Financing to Advance Oral Antibodies for Inflammatory Bowel Disease
11. GeneTex Antibody Company to Launch New Line of Primary Antibodies for the Study of Spindle Assembly
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... Proscia Inc ., ... a Webinar titled, “Pathology is going digital. Is your lab ready?” with Dr. ... best practices and how Proscia improves lab economics and realizes an increase in ...
(Date:10/11/2017)... and LAGUNA HILLS, Calif. , Oct. 11, ... Research, London (ICR) and University of ... SkylineDx,s prognostic tool to risk-stratify patients with multiple myeloma (MM), ... nine . The University of Leeds ... funded by Myeloma UK, and ICR will perform the testing ...
(Date:10/11/2017)... ... October 11, 2017 , ... A new study published in ... and fresh in vitro fertilization (IVF) transfer cycles. The multi-center matched ... , After comparing the results from the fresh and frozen transfer cohorts, the ...
(Date:10/10/2017)... , ... October 10, 2017 , ... San Diego-based team ... its corporate rebranding initiative announced today. The bold new look is part of ... the company moves into a significant growth period. , It will also expand its ...
Breaking Biology Technology:
(Date:4/11/2017)... , April 11, 2017 No two ... researchers at the New York University Tandon School ... Engineering have found that partial similarities between prints ... used in mobile phones and other electronic devices ... The vulnerability lies in the fact that ...
(Date:4/5/2017)... KEY FINDINGS The global market for stem ... 25.76% during the forecast period of 2017-2025. The rise ... growth of the stem cell market. Download ... The global stem cell market is segmented on the ... cell market of the product is segmented into adult ...
(Date:3/30/2017)... -- Trends, opportunities and forecast in this market to ... AFIS, iris recognition, facial recognition, hand geometry, vein recognition, ... industry (government and law enforcement, commercial and retail, health ... and by region ( North America , ... , and the Rest of the World) ...
Breaking Biology News(10 mins):